Swamy Yeleswaram
Fortuna: 10 M $ al 31/05/2026
Fortuna: 10 M $ al 31/05/2026
Swamy Yeleswaram was the founder of Incyte Corp., founded in 2002, and held the title of Group Vice President-Drug Metabolism from 2016 to 2022.
Dr. Yeleswaram currently holds the position of Chief Development Officer at Rapport Therapeutics, Inc. since 2023.
Dr. Yeleswaram's education includes a doctorate from the University of British Columbia, a graduate degree from Banaras Hindu University, and an undergraduate degree from Madras Medical College.
| Empresa | Fecha | Número de acciones | Valoración | Fecha de valoración |
|---|---|---|---|---|
| 17/04/2026 | 246.426 ( 0,52 % ) | 10 M $ | 31/05/2026 |
| Empresas | Cargo | Inicio |
|---|---|---|
| RAPPORT THERAPEUTICS, INC. | Corporate Officer/Principal | 01/01/2023 |
| Empresas | Cargo | Fin |
|---|---|---|
| INCYTE CORPORATION | Fundador | 01/08/2022 |
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Relaciones de 1er grado
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
| Empresas privadas | 5 |
|---|---|
Incyte Corp.
Incyte Corp. Pharmaceuticals: MajorHealth Technology Engages in discovery, development and commercialization of proprietary therapeutics | Health Technology |
University of British Columbia
University of British Columbia Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Banaras Hindu University
Banaras Hindu University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Madras Medical College
Madras Medical College Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Rapport Therapeutics, Inc.
Rapport Therapeutics, Inc. BiotechnologyHealth Technology Operates as an clinical-stage biotechnology company that engages in discovery and development of medicines for neurological disorder | Health Technology |
Selecciona tu edición
Toda la información financiera adaptada al ámbito nacional.